{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:12:43Z","timestamp":1784041963025,"version":"3.55.0"},"reference-count":64,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T00:00:00Z","timestamp":1715731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Bristol Myers Squibb"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Ulcerative colitis (UC) is a severe and debilitating illness that affects the quality of life and physical health of many Canadians. Given the dynamic and progressive nature of the disease, advanced therapies are required to support its long-term management. The emergence of small molecule therapies offers novel treatment options that target mechanisms central to the immunopathology of UC. Sphingosine-1-phosphate (S1P) receptor modulators and Janus-activated kinase inhibitors are 2 classes of therapies that target unique pathways to attenuate inflammation and modulate the immune response characteristic of UC. This review aims to provide practical guidance on how these therapeutic options can best be used to optimize treatment management and highlight the emerging role of small molecule therapies as a treatment strategy for UC.<\/jats:p>","DOI":"10.1093\/jcag\/gwae013","type":"journal-article","created":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T16:51:32Z","timestamp":1715791892000},"page":"282-289","source":"Crossref","is-referenced-by-count":5,"title":["Practical guidance for managing patients with moderate-to-severe ulcerative colitis using small molecule therapies"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8603-898X","authenticated-orcid":false,"given":"Vipul","family":"Jairath","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Western University, St. Joseph\u2019s Health Care , London, ON , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waqqas","family":"Afif","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, McGill University, Montreal General Hospital , Montreal, QC H3G 1A4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Bressler","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, University of British Columbia , Vancouver, BC V5Z 1M9 , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1479-5302","authenticated-orcid":false,"given":"Janet E","family":"Pope","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, St Joseph\u2019s Hospital, Western University , London , ON N6A 4V2 , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Selchen","sequence":"additional","affiliation":[{"name":"Division of Neurology, Barlo Multiple Sclerosis Centre, Department of Medicine, St. Michael\u2019s Hospital, University of Toronto , Toronto, ON M5B 1W8 , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4366-9076","authenticated-orcid":false,"given":"Laura E","family":"Targownik","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, University of Toronto , Toronto, ON M5S 3H2 , Canada"},{"name":"Mount Sinai Hospital IBD Centre, Division of Gastroenterology, Mount Sinai Hospital , Toronto, ON M5G 1X5 , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5247-940X","authenticated-orcid":false,"given":"Remo","family":"Panaccione","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, University of Calgary , Calgary, AB T2N 4Z6 , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,15]]},"reference":[{"key":"2024081206511058900_CIT0001","article-title":"Ulcerative Colitis","volume-title":"StatPearls [Internet]","author":"Lynch","year":"2022"},{"key":"2024081206511058900_CIT0002","first-page":"1","volume-title":"Crohn\u2019s and Colitis Canada","author":"Crohn\u2019s and Colitis Canada","year":"2023"},{"key":"2024081206511058900_CIT0003","first-page":"1993","article-title":"An overview of the efficacy and safety of ozanimod for the treatment of relapsing multiple sclerosis","volume-title":"Drug Des Devel Ther","author":"Fronza","year":"2021"},{"key":"2024081206511058900_CIT0004","first-page":"102844","article-title":"Ozanimod in relapsing multiple sclerosis: pooled safety results from the clinical development program","volume-title":"Mult Scler Relat Disord","author":"Selmaj","year":"2021"},{"issue":"12","key":"2024081206511058900_CIT0005","first-page":"656","article-title":"Etiology and management of lack or loss of response to anti\u2013tumor necrosis factor therapy in patients with inflammatory bowel disease","volume":"15","author":"Fine","year":"2019","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"2024081206511058900_CIT0006","first-page":"302","article-title":"Therapeutic drug monitoring in inflammatory bowel disease: for every patient and every drug","volume-title":"Curr Opin Gastroenterol.","author":"Papamichael","year":"2019"},{"key":"2024081206511058900_CIT0007","first-page":"1280","article-title":"Ozanimod as induction and maintenance therapy for ulcerative colitis","volume-title":"N Engl J Med.","author":"Sandborn","year":"2021"},{"key":"2024081206511058900_CIT0008","first-page":"1120","article-title":"Long-term efficacy and safety of ozanimod in moderately to severely active ulcerative colitis: results from the open-label extension of the randomized, phase 2 TOUCHSTONE study","volume-title":"J Crohns Colitis.","author":"Sandborn","year":"2021"},{"key":"2024081206511058900_CIT0009","first-page":"900","article-title":"Regulation of JAK-STAT signalling in the immune system","volume-title":"Nat Rev Immunol.","author":"Shuai","year":"2003"},{"key":"2024081206511058900_CIT0010","first-page":"1281","article-title":"The JAK\/STAT signaling pathway","volume-title":"J Cell Sci.","author":"Rawlings","year":"2004"},{"key":"2024081206511058900_CIT0011","first-page":"405","article-title":"Increased mortality rates with prolonged corticosteroid therapy when compared with antitumor necrosis factor-\u03b1-directed therapy for inflammatory bowel disease","volume-title":"Am J Gastroenterol.","author":"Lewis","year":"2018"},{"key":"2024081206511058900_CIT0012","first-page":"630","article-title":"Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis","volume-title":"Am J Gastroenterol.","author":"Khan","year":"2011"},{"key":"2024081206511058900_CIT0013","first-page":"CD000478","article-title":"Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis","volume-title":"Cochrane Database Syst Rev","author":"Timmer","year":"2016"},{"key":"2024081206511058900_CIT0014","first-page":"1386","article-title":"The long-term efficacy of azathioprine in steroid-dependent ulcerative colitis","volume-title":"Scand J Gastroenterol.","author":"Park","year":"2013"},{"key":"2024081206511058900_CIT0015","first-page":"1450","article-title":"AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis","volume-title":"Gastroenterology.","author":"Feuerstein","year":"2020"},{"key":"2024081206511058900_CIT0016","first-page":"392","article-title":"Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis","volume-title":"Gastroenterology.","author":"Panaccione","year":"2014"},{"key":"2024081206511058900_CIT0017","first-page":"G155","article-title":"JAK inhibition using tofacitinib for inflammatory bowel disease treatment: A hub for multiple inflammatory cytokines","volume-title":"Am J Physiol Gastrointest Liver Physiol.","author":"Danese","year":"2016"},{"key":"2024081206511058900_CIT0018","first-page":"552","article-title":"Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial","volume-title":"Lancet (London, England)","author":"Bachelez","year":"2015"},{"key":"2024081206511058900_CIT0019","first-page":"1570","article-title":"STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD","volume-title":"Gastroenterology.","author":"Turner","year":"2021"},{"key":"2024081206511058900_CIT0020","first-page":"519","article-title":"JAK Inhibitors in rheumatoid arthritis: an evidence-based review on the emerging clinical data","volume-title":"J Inflamm Res","author":"Harrington","year":"2020"},{"key":"2024081206511058900_CIT0021","first-page":"175628642110355","article-title":"Treatment approaches to patients with multiple sclerosis and coexisting autoimmune disorders","volume-title":"Ther Adv Neurol Disord","author":"Brummer","year":"2021"},{"issue":"5","key":"2024081206511058900_CIT0022","first-page":"265","article-title":"Sphingosine-1 phosphate receptor modulators: the next wave of oral therapies in inflammatory bowel disease","volume":"18","author":"Choden","year":"2022","journal-title":"Gastroenterol Hepatol (N Y)."},{"key":"2024081206511058900_CIT0023","article-title":"Treatments for Multiple Sclerosis","author":"MS Canada [Internet]","year":"2023"},{"key":"2024081206511058900_CIT0024","first-page":"1","volume-title":"a Bristol Myers Squibb Company","author":"Celgene Inc","year":"2022"},{"key":"2024081206511058900_CIT0025","volume-title":"Velsipity (Etrasimod) Product Monograph","author":"Pfizer Inc","year":"2024"},{"key":"2024081206511058900_CIT0026","first-page":"1159","article-title":"Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies","volume-title":"Lancet (London, England)","author":"Sandborn","year":"2023"},{"key":"2024081206511058900_CIT0027","first-page":"1411","article-title":"Systematic review and network meta-analysis of treatment for moderate-to-severe ulcerative colitis","volume-title":"Int J Clin Pharm","author":"Trigo-Vicente","year":"2018"},{"key":"2024081206511058900_CIT0028","first-page":"1754","article-title":"Ozanimod induction and maintenance treatment for ulcerative colitis","volume-title":"N Engl J Med.","author":"Sandborn","year":"2016"},{"key":"2024081206511058900_CIT0029","first-page":"2","article-title":"Rapidity of ozanimod-induced symptomatic response and remission in patients with moderately to severely active ulcerative colitis:Results from the induction period of True North","volume":"4","author":"Siegmund","year":"2022","journal-title":"Gastroenterol Hepatol (N Y)."},{"key":"2024081206511058900_CIT0030","first-page":"i844","article-title":"P715 Achievement and maintenance of endoscopic, histologic, and combined outcomes after extended induction in Week 10 nonresponders of ozanimod: 2-year interim analysis of the True North open-label extension study","volume-title":"J Crohns Colitis.","author":"Vermeire","year":"2023"},{"key":"2024081206511058900_CIT0031","first-page":"F638","article-title":"Sphingosine-1-phosphate signaling in blood pressure regulation","volume-title":"Am J Physiol Renal Physiol.","author":"Intapad","year":"2019"},{"key":"2024081206511058900_CIT0032","first-page":"1","volume-title":"A Bristol Myers Squibb company [Internet]","author":"Celgene Inc","year":"2022"},{"key":"2024081206511058900_CIT0033","first-page":"495","article-title":"Modulation of sphingosine-1-phosphate in inflammatory bowel disease","volume-title":"Autoimmun Rev.","author":"Peyrin-Biroulet","year":"2017"},{"key":"2024081206511058900_CIT0034","first-page":"e72","article-title":"Canadian association of gastroenterology clinical practice guideline for immunizations in patients with Inflammatory Bowel Disease (IBD)\u2014Part 2: Inactivated Vaccines","volume-title":"J Can Assoc Gastroenterol","author":"Jones","year":"2021"},{"key":"2024081206511058900_CIT0035","first-page":"402","article-title":"Fingolimod and macular edema: pathophysiology, diagnosis, and management","volume-title":"Neurol Clin Pract.","author":"Cugati","year":"2014"},{"key":"2024081206511058900_CIT0036","first-page":"1432","article-title":"Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis","volume-title":"Ophthalmology.","author":"Zarbin","year":"2013"},{"key":"2024081206511058900_CIT0037","first-page":"685","article-title":"Evaluation of the short-, mid-, and long-term effects of tofacitinib on lymphocytes in patients with rheumatoid arthritis","volume-title":"Arthritis Rheumatol.","author":"van Vollenhoven","year":"2019"},{"key":"2024081206511058900_CIT0038","first-page":"266","article-title":"Clinical remission in patients with moderate-to-severe Crohn\u2019s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial","volume-title":"Lancet (London, England)","author":"Vermeire","year":"2017"},{"key":"2024081206511058900_CIT0039","first-page":"545","article-title":"Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): A double-blind, randomised, placebo-controlled, phase 3 trial","volume-title":"Lancet Neurol.","author":"Calabresi","year":"2014"},{"key":"2024081206511058900_CIT0040","volume-title":"Gilenya (fingolimod) product monograph","year":"2021"},{"key":"2024081206511058900_CIT0041","first-page":"5023","article-title":"Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases","volume-title":"J Med Chem.","author":"Clark","year":"2014"},{"key":"2024081206511058900_CIT0042","article-title":"Medication Reference Guide","author":"Arthritis Society Canada [Internet]","year":"2021"},{"key":"2024081206511058900_CIT0043","first-page":"737","article-title":"Positioning of tofacitinib in treatment of ulcerative colitis: a global perspective","volume-title":"Expert Rev Gastroenterol Hepatol","author":"Mishra","year":"2022"},{"key":"2024081206511058900_CIT0044","first-page":"1897","article-title":"Evaluating upadacitinib in the treatment of moderate-to-severe active ulcerative colitis: design, development, and potential position in therapy","volume-title":"Drug Des Devel Ther","author":"Napolitano","year":"2022"},{"key":"2024081206511058900_CIT0045","first-page":"1","article-title":"Tofacitinib in the treatment of ulcerative colitis","volume-title":"Wien Klin Wochenschr.","author":"Kutschera","year":"2023"},{"key":"2024081206511058900_CIT0046","first-page":"G155","article-title":"JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines","volume-title":"Am J Physiol Gastrointest Liver Physiol.","author":"Danese","year":"2016"},{"key":"2024081206511058900_CIT0047","first-page":"1","volume-title":"Rinvoq(R) Upadacitinib Product Monograph","author":"AbbVie Corporation","year":"2023"},{"key":"2024081206511058900_CIT0048","first-page":"1723","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume-title":"N Engl J Med.","author":"Sandborn","year":"2017"},{"key":"2024081206511058900_CIT0049","first-page":"2113","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials","volume-title":"Lancet (London, England)","author":"Danese","year":"2022"},{"key":"2024081206511058900_CIT0050","first-page":"139","article-title":"Tofacitinib induction therapy reduces symptoms within 3 days for patients with ulcerative colitis","volume-title":"Clin Gastroenterol Hepatol.","author":"Hanauer","year":"2019"},{"key":"2024081206511058900_CIT0051","first-page":"1821","article-title":"Efficacy and safety of extended induction with tofacitinib for the treatment of ulcerative colitis","volume-title":"Clin Gastroenterol Hepatol","author":"Sandborn","year":"2022"},{"key":"2024081206511058900_CIT0052","first-page":"1","volume-title":"Xeljanz(R) Tofacitinib Product Monograph","author":"Pfizer Canada ULC","year":"2023"},{"key":"2024081206511058900_CIT0053","volume-title":"Monitoring Strategies for Drug Treatment of Rheumatoid arthritis","author":"Up To Date. UpToDate, Inc","year":"2023"},{"key":"2024081206511058900_CIT0054","first-page":"1778","article-title":"Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity","volume-title":"Br J Pharmacol.","author":"Scott","year":"2016"},{"key":"2024081206511058900_CIT0055","first-page":"387","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume-title":"N Engl J Med.","author":"Kappos","year":"2010"},{"key":"2024081206511058900_CIT0056","article-title":"Clinical trial finds an increased risk of blood clots in the lungs and of death in rheumatoid arthritis patients taking high dose of tofacitinib (sold as Xeljanz or Xeljanz XR)","author":"Government of Canada. Recalls and Safety Alerts","year":"2019"},{"key":"2024081206511058900_CIT0057","first-page":"779","article-title":"Venous thromboembolism risk with JAK inhibitors: a meta-analysis","volume-title":"Arthritis Rheumatol.","author":"Yates","year":"2021"},{"key":"2024081206511058900_CIT0058","first-page":"189","article-title":"Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis","volume-title":"Ann Rheum Dis.","author":"Molander","year":"2023"},{"key":"2024081206511058900_CIT0059","first-page":"1451","article-title":"Initial experience with tofacitinib in clinical practice: treatment patterns and costs of tofacitinib administered as monotherapy or in combination with conventional synthetic DMARDs in 2 US health care claims databases","volume-title":"Clin Ther.","author":"Harnett","year":"2016"},{"key":"2024081206511058900_CIT0060","first-page":"173","article-title":"Postapproval comparative safety study of tofacitinib and biological disease-modifying antirheumatic drugs: 5-year results from a united states-based rheumatoid arthritis registry","volume-title":"ACR Open Rheumatol","author":"Kremer","year":"2021"},{"key":"2024081206511058900_CIT0061","first-page":"S755","article-title":"Jak inhibitors safety in ulcerative colitis: practical implications","volume-title":"J Crohns Colitis.","author":"Agrawal","year":"2020"},{"key":"2024081206511058900_CIT0062","volume-title":"Olumiant (baricitinib) product monograph","year":"2022"},{"key":"2024081206511058900_CIT0063","first-page":"2929","article-title":"Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis","volume-title":"Am J Gastroenterol.","author":"Kane","year":"2001"},{"key":"2024081206511058900_CIT0064","first-page":"1417","article-title":"Predictors of medication adherence in inflammatory bowel disease","volume-title":"Am J Gastroenterol.","author":"Ediger","year":"2007"}],"container-title":["Journal of the Canadian Association of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcag\/article-pdf\/7\/4\/282\/58797575\/gwae013.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcag\/article-pdf\/7\/4\/282\/58797575\/gwae013.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T07:36:10Z","timestamp":1723448170000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcag\/article\/7\/4\/282\/7674170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,15]]},"references-count":64,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,5,15]]},"published-print":{"date-parts":[[2024,8,12]]}},"URL":"https:\/\/doi.org\/10.1093\/jcag\/gwae013","relation":{},"ISSN":["2515-2084","2515-2092"],"issn-type":[{"value":"2515-2084","type":"print"},{"value":"2515-2092","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,8]]},"published":{"date-parts":[[2024,5,15]]}}}